Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7213471 | 0.82 | AXL (0.33) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL26970102 | 0.79 | PDE3B (0.32) | — | |
| SCHEMBL30251105 | 0.78 | CYP2A6 (0.39) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL7220040 | 0.78 | CYP2A6 (0.39) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL30946929 | 0.78 | LMNA (0.34) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL26970098 | 0.76 | KDM4E (0.34) | — | |
| SCHEMBL659154 | 0.76 | — | — | |
| SCHEMBL659948 | 0.76 | NOS3 (0.35) | MAPTHIPK2AXL | |
| SCHEMBL31107764 | 0.76 | CYP2A6 (0.46) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL31107763 | 0.76 | CYP2A6 (0.46) | LMNACYP3A4MAPTAPEX1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024215802-A1 | BENZOFURANYL AND BENZOTHIENYL COMPOUNDS AS P53 MODULATORS | NESTED THERAPEUTICS, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| US-8378104-B2 | 7-aminofuropyridine derivatives | OSI Pharmaceuticals, LLC (US) | 2013-02-19 | — | — | US | disclosed |
| EP-2534156-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI Pharmaceuticals, LLC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| WO-2011100502-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI Pharmaceuticals, LLC (US) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | MAP3K5, STK17A, MAPKAPK5 | LMNA 3566/4885CYP3A4 637/4885MAPT 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.